D-Minus Hemolytic Uremic Syndrome Treatments
Find D-Minus Hemolytic Uremic Syndrome Treatments
Medications for D-Minus Hemolytic Uremic Syndrome
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in D-Minus Hemolytic Uremic Syndrome.
Found 2 Approved Drugs for D-Minus Hemolytic Uremic Syndrome
Eculizumab
Brand Names
Soliris, BKEMV, Epysqli
Eculizumab
Brand Names
Soliris, BKEMV, Epysqli
Form: Injection
Method of administration: Intravenous
FDA approval date: April 02, 2007
Classification: Complement Inhibitor
EPYSQLI is a complement inhibitor indicated for: the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
Ultomiris
Generic Name
Ravulizumab
Ultomiris
Generic Name
Ravulizumab
Form: Solution
Method of administration: Intravenous
FDA approval date: December 21, 2018
Classification: Complement Inhibitor
ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH).
Showing 1-2 of 2
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances